10 November 2025 | Innovation & Research

InnoCore receives EU grant for the development of Sustained Release microspheres

Developing Sustained Release microspheres

InnoCore Pharmaceuticals has secured funding from the European Just Transition Fund to develop sustained release microspheres. During this project we will encapsulate a specific peptide within our proprietary and biodegradable SynBiosys® microspheres. In this project, InnoCore plans to develop a more effective and patient friendly treatment with a simplified administration.

Just Transition Fund

The Just Transition Fund (JTF) is a new instrument of the Cohesion Policy 2021-2027, as the first pillar of the Just Transition Mechanism in the context of the European Green Deal aiming at achieving the EU climate-neutrality by 2050.

The JTF supports the territories most affected by the transition towards climate neutrality to avoid regional inequalities growing, in line with EU cohesion policy’s aim to reduce regional disparities and to address structural changes in the EU.

The Commission has set up a Just Transition Platform to help EU countries and regions to unlock the support available through the Just Transition Mechanism.

About Innocore Pharmaceuticals:

Innocore Pharmaceuticals is a pharmaceutical drug delivery and development company focused on the development and clinical manufacturing of injectable sustained release dosage forms for the treatment of chronic and site-specific diseases. Utilizing its proprietary SynBiosys® and InGellTM  biodegradable polymeric drug delivery platforms, InnoCore develops long-acting injectable depots in the form of microparticles, implants and gels for precisely controlled delivery of therapeutic compounds, including small molecules, peptides and proteins. Over the years, InnoCore’s versatile drug delivery platforms have shown their safety and effectiveness in several pre-clinical and clinical trials. Since its inception in 2003, InnoCore has successfully established partnerships with biomedical, biotech and pharmaceutical companies.  In 2013, the first product with InnoCore’s SynBiosys® drug delivery technology incorporated received regulatory approval and is now available in the market. Innocore Pharmaceuticals is privately owned and located in Groningen, The Netherlands